



NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon's Liraglutide (gSaxenda®) Receive Approval from MHRA

Bengaluru, Karnataka, India, April 01, 2024

“Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda®) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity.

This is further to our previous intimation of 27th March, 2024, informing that approval was received from the MHRA for Liraglutide (gVicotza®), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva.

The approvals will further strengthen Biocon's portfolio of vertically integrated, complex drug products.”